AU2005282860B2 - Method of wound healing using A2B adenosine receptor antagonists - Google Patents

Method of wound healing using A2B adenosine receptor antagonists Download PDF

Info

Publication number
AU2005282860B2
AU2005282860B2 AU2005282860A AU2005282860A AU2005282860B2 AU 2005282860 B2 AU2005282860 B2 AU 2005282860B2 AU 2005282860 A AU2005282860 A AU 2005282860A AU 2005282860 A AU2005282860 A AU 2005282860A AU 2005282860 B2 AU2005282860 B2 AU 2005282860B2
Authority
AU
Australia
Prior art keywords
optionally substituted
methyl
dione
propyl
pyrazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2005282860A
Other languages
English (en)
Other versions
AU2005282860A1 (en
Inventor
Luiz Belardinelli
Dewan Zeng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of AU2005282860A1 publication Critical patent/AU2005282860A1/en
Assigned to GILEAD PALO ALTO, INC. reassignment GILEAD PALO ALTO, INC. Alteration of Name(s) of Applicant(s) under S113 Assignors: CV THERAPEUTICS, INC.
Application granted granted Critical
Publication of AU2005282860B2 publication Critical patent/AU2005282860B2/en
Assigned to GILEAD SCIENCES, INC. reassignment GILEAD SCIENCES, INC. Request for Assignment Assignors: GILEAD PALO ALTO, INC.
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
AU2005282860A 2004-09-01 2005-08-30 Method of wound healing using A2B adenosine receptor antagonists Expired AU2005282860B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60667504P 2004-09-01 2004-09-01
US60/606,675 2004-09-01
PCT/US2005/030838 WO2006028810A2 (en) 2004-09-01 2005-08-30 Method of wound healing using a2b adenosine receptor antagonists

Publications (2)

Publication Number Publication Date
AU2005282860A1 AU2005282860A1 (en) 2006-03-16
AU2005282860B2 true AU2005282860B2 (en) 2012-03-22

Family

ID=35695744

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005282860A Expired AU2005282860B2 (en) 2004-09-01 2005-08-30 Method of wound healing using A2B adenosine receptor antagonists

Country Status (21)

Country Link
US (1) US20060058322A1 (cg-RX-API-DMAC7.html)
EP (1) EP1789053B1 (cg-RX-API-DMAC7.html)
JP (2) JP4929173B2 (cg-RX-API-DMAC7.html)
KR (1) KR101247528B1 (cg-RX-API-DMAC7.html)
CN (1) CN101043889B (cg-RX-API-DMAC7.html)
AU (1) AU2005282860B2 (cg-RX-API-DMAC7.html)
CA (1) CA2578702A1 (cg-RX-API-DMAC7.html)
DK (1) DK1789053T3 (cg-RX-API-DMAC7.html)
ES (1) ES2387653T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20120712T1 (cg-RX-API-DMAC7.html)
IL (1) IL181634A (cg-RX-API-DMAC7.html)
MX (1) MX2007002437A (cg-RX-API-DMAC7.html)
NO (1) NO20071718L (cg-RX-API-DMAC7.html)
NZ (1) NZ553487A (cg-RX-API-DMAC7.html)
PL (1) PL1789053T3 (cg-RX-API-DMAC7.html)
PT (1) PT1789053E (cg-RX-API-DMAC7.html)
RS (1) RS52455B (cg-RX-API-DMAC7.html)
RU (1) RU2385322C2 (cg-RX-API-DMAC7.html)
SI (1) SI1789053T1 (cg-RX-API-DMAC7.html)
WO (1) WO2006028810A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200701777B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1658291B1 (en) 2003-08-25 2013-10-02 Dogwood Pharmaceuticals, Inc. Substituted 8-heteroaryl xanthines
EP2311462A1 (en) 2004-10-15 2011-04-20 Cv Therapeutics, Inc. Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists
WO2006091897A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Derivatives of 8-substituted xanthines
US7598379B2 (en) * 2005-02-25 2009-10-06 Pgx Health, Llc Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
WO2006091898A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Pyrazolyl substituted xanthines
CA2612344A1 (en) * 2005-06-16 2006-12-28 Cv Therapeutics, Inc. Prodrugs of a2b adenosine receptor antagonists
US7884100B2 (en) 2006-06-16 2011-02-08 Pgxhealth, Llc Substituted 8-[6-amino-3-pyridyl]xanthines
US7767685B2 (en) * 2006-06-29 2010-08-03 King Pharmaceuticals Research And Development, Inc. Adenosine A2B receptor antagonists
JP5460690B2 (ja) * 2008-03-26 2014-04-02 アドヴィナス・セラピューティックス・リミテッド アデノシンレセプターアンタゴニストとしてのヘテロ環化合物
JP7849948B2 (ja) * 2018-03-05 2026-04-22 テオン セラピューティクス,インク. アデノシン受容体アンタゴニストおよびその使用
CN108864114B (zh) * 2018-06-04 2020-11-06 应世生物科技(南京)有限公司 选择性a2a受体拮抗剂
EP4211135A1 (en) * 2020-09-04 2023-07-19 Teon Therapeutics, Inc. Cocrystals of an adenosine a2b receptor antagonist

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030229106A1 (en) * 2001-11-09 2003-12-11 Rao Kalla A2B adenosine receptor antagonists

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452788A (en) * 1982-04-21 1984-06-05 Warner-Lambert Company Substituted 8-phenylxanthines
US4593095A (en) * 1983-02-18 1986-06-03 The Johns Hopkins University Xanthine derivatives
US4558051A (en) * 1983-10-11 1985-12-10 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same
GB8510758D0 (en) * 1985-04-27 1985-06-05 Wellcome Found Compounds
DE3843117A1 (de) * 1988-12-22 1990-06-28 Boehringer Ingelheim Kg Neue xanthinderivate mit adenosin-antagonistischer wirkung
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
WO1994023723A1 (en) * 1993-04-15 1994-10-27 New York University Adenosine receptor agonists for the promotion of wound healing
US5446046A (en) * 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
GB9415529D0 (en) * 1994-08-01 1994-09-21 Wellcome Found Phenyl xanthine derivatives
DE19535504A1 (de) * 1995-09-25 1997-03-27 Bayer Ag Substituierte Xanthine
GB9703044D0 (en) * 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
US6060481A (en) * 1998-05-28 2000-05-09 The Penn State Research Foundation Method for improving insulin sensitivity using an adenosine receptor antagonist
US6545002B1 (en) * 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
US6894021B2 (en) * 2000-02-17 2005-05-17 Cv Therapeutics, Inc. Method for identifying and using A2B adenosine receptor antagonists to mediate mammalian cell proliferation
US20020065286A1 (en) * 2000-08-21 2002-05-30 Davies Michael John Treatment of wounds
US7490726B2 (en) * 2001-09-06 2009-02-17 Alexander Virvo Soft toy holder
US6437154B1 (en) * 2001-09-28 2002-08-20 Council Of Scientific And Industrial Research Process for the preparation of 10-deacetylbaccatin III
AU2002359365B2 (en) * 2001-11-09 2008-07-10 Gilead Sciences, Inc. A2B adenosine receptor antagonists
US7317017B2 (en) * 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
JP4051481B2 (ja) * 2002-11-29 2008-02-27 ヤマハマリン株式会社 船外機
EP1636229A4 (en) * 2003-06-06 2008-07-30 Endacea Inc ADENOSINE A1 RECEPTOR ANTAGONISTS
US7449473B2 (en) * 2003-10-31 2008-11-11 Cv Therapeutics, Inc. Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030229106A1 (en) * 2001-11-09 2003-12-11 Rao Kalla A2B adenosine receptor antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Nantwi, K.D. et al. Neuropharmacology (1998) Vol.37 pages 113 to 121 *

Also Published As

Publication number Publication date
CN101043889A (zh) 2007-09-26
IL181634A (en) 2015-05-31
PL1789053T3 (pl) 2012-12-31
JP2011246492A (ja) 2011-12-08
JP4929173B2 (ja) 2012-05-09
PT1789053E (pt) 2012-08-09
ES2387653T3 (es) 2012-09-27
WO2006028810A3 (en) 2006-09-28
US20060058322A1 (en) 2006-03-16
WO2006028810A2 (en) 2006-03-16
RU2385322C2 (ru) 2010-03-27
DK1789053T3 (da) 2012-08-06
HK1107261A1 (en) 2008-04-03
CN101043889B (zh) 2010-11-03
NZ553487A (en) 2010-09-30
RU2007107605A (ru) 2008-09-10
KR101247528B1 (ko) 2013-04-15
MX2007002437A (es) 2007-08-14
HRP20120712T1 (hr) 2012-10-31
CA2578702A1 (en) 2006-03-16
RS52455B (sr) 2013-02-28
KR20070047816A (ko) 2007-05-07
AU2005282860A1 (en) 2006-03-16
EP1789053B1 (en) 2012-06-13
EP1789053A2 (en) 2007-05-30
ZA200701777B (en) 2008-09-25
NO20071718L (no) 2007-03-30
JP2008511654A (ja) 2008-04-17
IL181634A0 (en) 2007-07-04
SI1789053T1 (sl) 2012-09-28

Similar Documents

Publication Publication Date Title
AU2007227021B2 (en) Method of preventing and treating hepatic disease using A2B adenosine receptor antagonists
JP2011246492A (ja) A2bアデノシンレセプターアンタゴニストを使用する創傷治癒の方法
AU2004292529B2 (en) A2B adenosine receptor antagonists
AU2005295654B2 (en) Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists
HK1107261B (en) Method of wound healing using a2b adenosine receptor antagonists
AU2011202523B2 (en) A2B adenosine receptor antagonists

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: GILEAD SCIENCES, INC.

Free format text: FORMER APPLICANT(S): GILEAD PALO ALTO, INC.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired